<DOC>
	<DOCNO>NCT01646801</DOCNO>
	<brief_summary>The purpose study demonstrate Safety effectiveness use NMB 's drug eject balloon treatment de novo restenotic lesion peripheral arterial disease .</brief_summary>
	<brief_title>Study NMB Drug Ejecting Balloon Peripheral Arteries</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Patients 18 year old old Patient lifestyle limit claudication rest pain ( Rutherford Becker scale 2 , 3 4 ) . Patient de novo lesion restenotic lesion â‰¥70 % iliac , femoral , popliteal tibial artery . The target lesion successfully cross guide wire dilate . The target lesion native artery 2.510mm diameter less 80 mm length . Patient willing able sign write informed consent comply procedure ( e.g. , adherence followup visit , include 6 month CTangiography/MRA followup ) . Women pregnant breastfeed woman childbearing potential use adequate contraception . Previous participation another study investigational drug device within past 30 day . The patient currently enrol another investigational device drug trial . Severe reaction contrast agent adequately premedicated prior procedure . Stenosis correspond thrombosis treat within 7 day enrollment . Patient known contraindication aspirin anticoagulant/antiplatelet therapy . Patient comorbid illness may result life expectancy le 12 month . History haemorrhagic stroke gastrointestinal bleeding within 6 month . Patient major surgery 30 day precede interventional procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>